Media Center
-
Statement of Lymphoma Research Foundation on Access to Treatment
Policymakers in Washington, DC, and state capitols are considering measures to address the cost of health care, including prescription drugs, and to address insurance adequacy issues. As debate on these initiatives intensifies, we urge that policymakers consider the needs of people with lymphoma and lymphoma survivors.
-
Statement Of Lymphoma Research On Access To Quality Cancer Care In Response To Dobbs V. Jackson Women’s Health Organization
Statement of Lymphoma Research on Access to Quality Cancer Care In Response to Dobbs V.…
-
What Lymphoma Patients Need to Know About Current Treatments for COVID-19
As of mid-2022, there are a number of treatments for COVID-19 that have been either approved by the FDA or have been authorized for emergency use (EUA).
-
Lymphoma Research Foundation Names Sarah Quinlan Chief Program Officer
Lymphoma Research Foundation Names Sarah Quinlan Chief Program Officer The Lymphoma Research Foundation (LRF) –…
-
U.S. Food and Drug Administration Approves Lisocabtagene Maraleucel (BREYANZI) for Large B-Cell Lymphoma
The U.S. Food and Drug Administration Approves Lisocabtagene Maraleucel (Breyanzi) for Large B-Cell Lymphoma On…
MEDIA INQUIRIES:
We welcome members of the press to contact our Communications team at media@lymphoma.org with any media-related questions or interview requests.
